B
Bull
Bull · 25%SLN
$2.94
Scenario price
$8.870
-0.717 (-8.08%)At close
Loading chart…
- High
- 9.565
- Open
- 9.530
- VWAP
- 9.05
- Volume
- 1.45M
- Mkt Cap
- 886.54M
- Low
- 8.710
- Amount
- 13.12M
- EV/EBITDA, TTM
- -6.76
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
AI analysis of Silence Therapeutics PLC (SLN)
BuySilence Therapeutics PLC (SLN) is a good buy right now due to its recent positive developments and potential for growth. The current price is $9.86, and despite a recent 5-day decline of 7.33%, the stock has shown a year-to-date increase of 60.33%. The RSI is at 27.501, indicating that the stock is oversold, which could present a buying opportunity. Additionally, the gross margin has significantly improved to 97.39% in the latest quarter, reflecting strong operational efficiency. However, a key risk is the ongoing net losses, with a reported loss of $12.27 million in Q2 2026, which could impact investor sentiment in the short term.
Valuation Metrics
The current forward P/E ratio for Silence Therapeutics PLC (SLN) is 0.00, compared to its 5-year average forward P/E of -14.68.
Alphio AI Price Scenarios for SLN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SLN
Events Timeline
News
8.508-14NewsfilterSilence Therapeutics Closes $201.3 Million Public Offering
- 8.508-12Newsfilter
Silence Therapeutics Prices Public Offering at $13.50 per ADS
8.508-11NASDAQ.COMSilence Therapeutics Proposes $150 Million Public Offering
8.508-11NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Positive Catalysts
- 7.508-10Newsfilter
Socket Mobile Partners with 3Eye Technologies to Expand Distribution
SLN FAQ — answered by Alphio AI
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Silence Therapeutics PLC (SLN) is a good buy right now due to its recent positive developments and potential for growth. The current price is $9.86, and despite a recent 5-day decline of 7.33%, the stock has shown a year-to-date increase of 60.33%. The RSI is at 27.501, indicating that the stock is oversold, which could present a buying opportunity. Additionally, the gross margin has significantly improved to 97.39% in the latest quarter, reflecting strong operational efficiency. However, a key risk is the ongoing net losses, with a reported loss of $12.27 million in Q2 2026, which could impact investor sentiment in the short term.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.